<DOC>
	<DOC>NCT00468611</DOC>
	<brief_summary>This study will assess the efficacy and safety of MBP8298 compared to placebo in subjects with Secondary Progressive Multiple Sclerosis (SPMS)</brief_summary>
	<brief_title>Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
	<criteria>Male of female subjects, 1865 years of age with a diagnosis of SPMS HLA DR2 and/or DR4 positive Absence of a relapse in the 3 months prior to baseline EDSS of 3.0 6.5 Therapy with Betainterferon, glatiramer acetate within 3 months or mitoxantrone, cyclophosphamide, methotrexate, azathioprine or any immune modulating or immunosuppressive drugs within 6 months of baseline Treatment with Tysabri within 2 years of baseline Females who are breast feeding, pregnant (pregnancy test at baseline) or not using a medically approved method of contraception regularly Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Secondary Progressive Multiple Sclerosis</keyword>
	<keyword>Multiple Sclerosis</keyword>
</DOC>